DOI: 10.4244/EIJ-D-18-00500L

Is transcatheter aortic valve implantation feasible in patients with chronic kidney disease?

Rajkumar Doshi1*, MD, MPH; Jay Shah2, MD

We read the article “Transcatheter aortic valve implantation versus conservative treatment in chronic kidney disease patients.” by Steinmetz et al1 with great interest. This is a “non-randomised” and “single-centre” study. The authors compared transcatheter aortic valve implantation (TAVI) to conservative medical therapy in stage 3-5 chronic kidney disease (CKD) patients. They demonstrated that TAVI is associated with improved survival at one year compared to conservative therapy. This study is of vital importance as many of the physicians are hesitant to refer advanced stage CKD patients for TAVI as the data have been conflicting in previous studies. We agree that the prevalence of CKD is very high in aortic stenosis patients undergoing TAVI and that CKD alone is an independent predictor of adverse outcomes2. Many of the previous studies have demonstrated that TAVI is associated with fewer adverse events in advanced CKD patients when compared to surgical aortic valve replacement3,4. However, we have a few concerns which need to be clarified before these results gain wider uptake.

1. The results are not accompanied by the Society of Thoracic Surgeons (STS) score or EuroSCORE II which are major determinants for a decision to perform TAVI in most cases.

2. All-cause mortality for the conservative group may not be sufficient. The authors need to include cardiovascular mortality as well.

3. How many patients were already on dialysis prior to the study? Additional information is warranted as to how many patients had acute kidney injury post TAVI and how many received dialysis post TAVI.

4. Did any patient receive TAVI or surgical repair/replacement after diagnosis of aortic stenosis in the conservative management group?

Conflict of interest statement

The authors have no conflicts of interest to declare.

Volume 14 Number 17
Apr 16, 2019
Volume 14 Number 17
View full issue


Key metrics

Suggested by Cory

CLINICAL RESEARCH

10.4244/EIJ-D-18-00058 Aug 3, 2018
Transcatheter aortic valve implantation versus conservative treatment in chronic kidney disease patients
Steinmetz T et al
free

Editorial

10.4244/EIJ-E-24-00006 Apr 15, 2024
The miracle of left ventricular recovery after transcatheter aortic valve implantation
Dauerman H and Lahoud R
free

10.4244/EIJV15I17A268 Apr 17, 2020
Transcatheter aortic valve implantation in nonagenarians – old…but not obsolete!
Grube E and Sinning J
free
Trending articles
310.93

State-of-the-Art Review

10.4244/EIJ-D-21-00695 Nov 19, 2021
Transcatheter treatment for tricuspid valve disease
Praz F et al
free
172.13

Focus article

10.4244/EIJY19M08_01 Jan 17, 2020
EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update
Glikson M et al
free
92.2

State-of-the-Art Review

10.4244/EIJ-D-20-01296 Aug 27, 2021
Management of cardiogenic shock
Thiele H et al
free
76.25

State-of-the-Art

10.4244/EIJ-D-23-00840 Sep 2, 2024
Aortic regurgitation: from mechanisms to management
Baumbach A et al
free
56.65

Clinical research

10.4244/EIJ-D-20-01155 Oct 20, 2021
A deep learning algorithm for detecting acute myocardial infarction
Liu W et al
free
35

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved